Global biotechnology firm announces Evolva acquisition

The deal was completed last month (December 2023) and saw the acquisition of Evolva from parent company Evolva Holding by a Lallemand subsidiary based in Switzerland Danstar Ferment.

Initially announced to the Swiss Stock Exchange on 21 November, the transaction was approved by Evolva Holding shareholders at an extraordinary general meeting in late December.

Evolva is headquartered in Reinach, Basel, and employees 48 members of staff. It is focused on the research, development and commercialisation of natural ingredients derived from yeast for applications across the flavors and fragrances, health ingredients, cosmetics and health protection sectors.

Meanwhile, Lallemand is a global organisation with a presence in more than 50 countries including the UK, where it operates 48 production plants and employs around 5,000 people. The family-owned business specialises in the development, production and marketing of yeasts, bacteria, fungi and enzyme solutions across the baking, food ingredients, human and animal nutrition, health, crop protection and nutrition, oenology, brewing, alcohol and biofuel sectors.

Speaking following the announcement, Lallemand Bio-Ingredients president Lars Asferg described Evolva as a โ€œstrong strategic fitโ€‹โ€ alongside the firmโ€™s yeast-based technology platform

โ€œEvolvaโ€™s proprietary precision fermentation technology and R&D capabilities presents an ideal platform from which to expand our product offering mainly within health ingredients like Veri-te resveratrol and flavour and fragrance aroma components like Valencene and natural Nootkatone,โ€ โ€‹added Asferg.

Source link


Leave a Reply

Your email address will not be published. Required fields are marked *